Company intelligence / Profile preview

Dexlevo

Gangnam-gu, Seoul, South Koreadexlevo.co.kr ↗

Ownership: Private
Development stage: Commercial

Overview

Dexlevo has developed GOURI—the world’s first fully solubilized liquid polycaprolactone (PCL) injectable. GOURI has CE certification for use as a medical device/filler in Europe and other regions. Clinical trials are underway to obtain regulatory approval in South Korea. The product promotes natural collagen regeneration throughout the face with minimal invasiveness and without forming lumps or nodules.

Therapeutic areas: Dermatology
Modalities: BiologicPolymer-based injectable (specifically Polycaprolactone-based)Medical device
Industry: Biotech

Drug pipeline

1 asset

DLMR01

Unknown

Partnerships

Hugel (MOU signed)Multiple global distribution companies across Spain, UAE, Saudi Arabia, North Africa/MENA region

Beyond the preview

Go deeper on Dexlevo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dexlevo.

Explore the full profile